TOLEDO, Ohio--(BUSINESS WIRE)--NAMSA, the world’s only 100% medical device-focused Contract Research Organization (CRO) offering end-to-end development solutions, is pleased to announce the launch of its new website. Providing visitors a modern, user-friendly experience, the new site delivers extensive educational resources and development insights to assist global Sponsors with accelerated commercialization of life-saving medical device technologies.
Furthermore, the new site showcases NAMSA’s rich history and deep-rooted expertise in providing manufacturers with proven solutions critical to proactive management of global development requirements. Since 1967, NAMSA has assisted tens of thousands of medical device Sponsors in successfully addressing varying requirements and challenges pertaining to clinical research; medical device testing; and regulatory, quality and reimbursement requirements in every major market in the world.
“Enhancing clients’ online experience and providing insight into NAMSA’s development expertise and knowledge is critical as CRO competition continues to intensify,” stated Chris Rupp, Vice President of Global Marketing and Commercial Operations. “Although there are many CRO options for medical device manufacturers, NAMSA remains the world’s only 100% medical device-focused, full continuum CRO with documented benefits, including independently verified time and cost savings over industry averages,” Rupp continued.
While the international medical device marketplace is expected to grow to $506B by 2022 (GlobalData), there are very real challenges in front of device Sponsors. In recent years, the criteria for medical device research and conduct have been subject to expanded regulatory oversight and clinical evidence requirements, including that of EU MDR and IVDR. This potentially poses more complicated, time-consuming and costly activities for manufacturers, putting product novelty and market introduction at risk. Coupled with the challenge of the COVID-19 Pandemic, including limited resources for many Sponsors, it is even more important for device developers to select a CRO that possesses the expertise, knowledge and proven track record to proactively meet these requirements head-on.
“At the heart of our success is our in-depth therapeutic knowledge, global regulatory expertise and most importantly—our Associates’ dedication to bringing life-enhancing technologies to the marketplace in a safe, efficacious manner. The unwavering commitment of our 1,000+ Associates across more than ten countries is what inspires us every day and what allows for continued client innovation and commercialization success,” Rupp concluded.
To view NAMSA’s new website, please visit www.namsa.com.
Helping medical device Sponsors improve healthcare since 1967, NAMSA is the only 100% medical device-focused, full continuum Contract Research Organization (CRO). Driven by our global regulatory expertise and in-depth therapeutic knowledge, NAMSA is dedicated to accelerating medical device product development, offering only the most proven solutions to move clients’ products through the development lifecycle efficiently and cost-effectively. From medical device testing; regulatory, reimbursement and quality consulting; and clinical research services, we are the industry’s premier, trusted partner for successful development and commercialization outcomes.